niacinamide has been researched along with Mucositis, Oral in 11 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 9.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
| " Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC)." | 7.79 | Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ( Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013) |
| "Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib." | 7.76 | Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. ( Sahai, S; Swick, BL, 2010) |
| "Minocycline is another possible alternative therapy for pemphigus vulgaris." | 7.71 | [Oral pemphigus vulgaris. Successful treatment with minocycline and nicotinamide]. ( Beltraminelli, H; Büchner, SA; Gutersohn, T; Häusermann, P; Rufli, T; Schiller, P, 2002) |
| "We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab." | 5.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
| " Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC)." | 3.79 | Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ( Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013) |
| "Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib." | 3.76 | Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. ( Sahai, S; Swick, BL, 2010) |
| "The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses." | 3.75 | Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. ( Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009) |
| "Minocycline is another possible alternative therapy for pemphigus vulgaris." | 3.71 | [Oral pemphigus vulgaris. Successful treatment with minocycline and nicotinamide]. ( Beltraminelli, H; Büchner, SA; Gutersohn, T; Häusermann, P; Rufli, T; Schiller, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwartzberg, LS | 1 |
| Tauer, KW | 1 |
| Hermann, RC | 1 |
| Makari-Judson, G | 1 |
| Isaacs, C | 1 |
| Beck, JT | 1 |
| Kaklamani, V | 1 |
| Stepanski, EJ | 1 |
| Rugo, HS | 1 |
| Wang, W | 1 |
| Bell-McGuinn, K | 1 |
| Kirshner, JJ | 1 |
| Eisenberg, P | 1 |
| Emanuelson, R | 1 |
| Keaton, M | 1 |
| Levine, E | 1 |
| Medgyesy, DC | 1 |
| Qamar, R | 1 |
| Starr, A | 1 |
| Ro, SK | 1 |
| Lokker, NA | 1 |
| Hudis, CA | 1 |
| Noda, S | 1 |
| Shioya, M | 1 |
| Hira, D | 1 |
| Fujiyama, Y | 1 |
| Morita, SY | 1 |
| Terada, T | 1 |
| Marschner, N | 1 |
| Müller, L | 1 |
| Münch, A | 1 |
| Blumenstengel, K | 1 |
| Hutzschenreuter, U | 1 |
| Busies, S | 1 |
| Lee, WJ | 1 |
| Lee, JL | 1 |
| Chang, SE | 1 |
| Lee, MW | 1 |
| Kang, YK | 1 |
| Choi, JH | 1 |
| Moon, KC | 1 |
| Koh, JK | 1 |
| Sahai, S | 1 |
| Swick, BL | 1 |
| Janssens, GO | 1 |
| Terhaard, CH | 1 |
| Doornaert, PA | 1 |
| Bijl, HP | 1 |
| van den Ende, P | 1 |
| Chin, A | 1 |
| Pop, LA | 1 |
| Kaanders, JH | 1 |
| Häusermann, P | 1 |
| Gutersohn, T | 1 |
| Beltraminelli, H | 1 |
| Schiller, P | 1 |
| Büchner, SA | 1 |
| Rufli, T | 1 |
| Tischendorf, L | 1 |
| Cowan, DH | 1 |
| Alison, RE | 1 |
| MacLeod, RD | 1 |
| Du Plessis, JP | 1 |
| Wittmann, W | 1 |
| Groothof, G | 1 |
| Laubscher, NF | 1 |
| de Villiers, R | 1 |
| Louw, ME | 1 |
| Alberts, A | 1 |
| Kruger, H | 1 |
| van Twisk, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636] | Phase 2 | 160 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy[NCT00610012] | 1,500 participants (Actual) | Observational [Patient Registry] | 2007-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 94 |
| B (Placebo + Gemcitabine or Capecitabine) | 147 |
Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.
| Intervention | percentage of participants (Number) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 19.8 |
| B (Placebo + Gemcitabine or Capecitabine) | 12.7 |
(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 407 |
| B (Placebo + Gemcitabine or Capecitabine) | 348 |
(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 103 |
| B (Placebo + Gemcitabine or Capecitabine) | 81 |
(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.
| Intervention | Days (Median) |
|---|---|
| A (Sorafenib + Gemcitabine or Capecitabine) | 111 |
| B (Placebo + Gemcitabine or Capecitabine) | 82 |
4 trials available for niacinamide and Mucositis, Oral
| Article | Year |
|---|---|
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Carbon Dioxide; Carcinoma, Squamous Cell; Deglut | 2012 |
Evaluation of 6-aminonicotinamide (NSC-21206) in the treatment of metastatic hypernephroma.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Follow-U | 1970 |
Abnormal tongue appearances and vitamin status of the elderly--a double blind trial.
Topics: Aged; Ascorbic Acid; Capillary Fragility; Clinical Trials as Topic; Glossitis, Benign Migratory; Hum | 1972 |
7 other studies available for niacinamide and Mucositis, Oral
| Article | Year |
|---|---|
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Hepatocellular; | 2013 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; | 2017 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfon | 2009 |
Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Nia | 2010 |
[Oral pemphigus vulgaris. Successful treatment with minocycline and nicotinamide].
Topics: Adult; Drug Therapy, Combination; Female; Humans; Minocycline; Mouth Mucosa; Niacinamide; Pemphigus; | 2002 |
[Local nicotinamide therapy in erosive lichen of the oral mucosa].
Topics: Administration, Topical; Chloroquine; Humans; Lichen Planus; Niacinamide; Risk; Stomatitis; Triamcin | 1978 |
Effect of enrichment of maize meal with nicotinic acid and riboflavin upon the vitamin and protein nutritional status of young school-going and pre-school children.
Topics: Arm; Black or African American; Black People; Child; Child, Preschool; Darier Disease; Diet; Food, F | 1974 |